- Signaling Pathways
- Cytoskeleton
- Integrin
Integrin
Integrins, a family of heterodimeric adhesion receptors for diverse extracellular matrices, have consistently been implicated as crucial drivers of ovarian cancer development and progression. A number of the RGD-based members of the integrin family, including α5β1, and αvβ3 or αvβ5 integrins, are markedly elevated in aggressive ovarian tumors. These adhesion receptors appear to promote cell adhesion, survival, motility and invasion during ovarian tumor growth or metastatic progression. Importantly, the functions of these integrins are strongly dependent on the activation of focal adhesion kinase (FAK) and its downstream signaling, including the PI3K/Akt- and Ras/MAPK-dependent pathways.
Integrins are transmembrane proteins and are major receptors for cell-extracellular matrix (ECM) and cell-cell adhesion. Modulation of these molecules, particularly αv integrin family, has exhibited profound effects on fibrosis in multiple organ and disease state. Based on the several studies, the integrins αvβ3, αvβ5, αvβ6, and αvβ8 have been known to modulate the fibrotic process via activation of latent transforming growth factor (TGF)-β in pre-clinical models of fibrosis.
Each integrin is typically formed by the non-covalent pairing of one α subunit, of which, 18 types are known to exist, and one β subunit, of which 8 types are known to exist. Together, 24 distinct heterodimers have been identified to date. The αv subunit can form heterodimers with the β1, β3, β5, β6 or β8 subunits and β1 can associate with many different α subunits from α1 to α11, and αv, indicating that not all theoretically possible α and subunit pairs form. Interestingly, the activation of TGF-β appears to be a common function of multiple αv integrins.
Integrin Isoform Specific Products
-
Integrin
(380)
View all products
-
αvβ1
(6)
View all products
-
αvβ3
(31)
View all products
-
αvβ5
(10)
View all products
-
αvβ6
(21)
View all products
-
αvβ8
(7)
View all products
-
α5β1
(17)
View all products
-
α1β1
(3)
View all products
-
α2β1
(6)
View all products
-
α4β1
(22)
View all products
-
α9β1
(4)
View all products
-
αIIbβ3
(7)
View all products
-
α4β7
(17)
View all products
-
αLβ2
(2)
View all products
All Product Categories
-
Integrin Inhibitors
(240)
View all products
-
Integrin Agonists
(9)
View all products
-
Integrin Antagonists
(96)
View all products
-
Integrin Activators
(7)
View all products
-
Integrin Modulators
(6)
View all products
-
Integrin Chemicals
(2)
View all products
-
Integrin Inducers
(3)
View all products
-
Integrin Degrader
(1)
View all products
-
Integrin Controls
(4)
View all products
-
Integrin Substrate
(1)
View all products
-
Integrin Ligands
(26)
View all products
-
Integrin alpha 1 beta 1 Proteins
(2)
View all products
-
Integrin alpha V beta 3 Proteins
(5)
View all products
-
Integrin alpha V beta 5 Proteins
(4)
View all products
-
Integrin alpha V beta 6 Proteins
(8)
View all products
-
Integrin alpha V beta 8 Proteins
(8)
View all products
-
Integrin Related Products (501)
Related Products (501)
-
Recombinant Proteins (27)
-
Antibodies (31)
-
Integrin Isoform Comparison
-
SR121566A
0 ImagesCat. No.: HY-U00235CAS No.: 180144-61-0SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50s of 46±7.5, 56±6 and 42±3 nM, respectively. -
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
No matching results
No matching results
No matching results
No matching results
-
loading...Please select quantityGet Quote
August 31
-
Please select quantity
August 31
Get Quote
loading... -
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
No matching results
Your Search Returned No Results.
Sorry. There is currently no product that acts on isoform Bcl-2, Bcl-W and Bim together.Please
try each isoform separately.